Abstract: The present disclosure relates to a method of treating a subject having a proinflammatory endophenotype profile with celecoxib or naproxen to improve cognition or to prevent cognitive decline or dysfunction in the subject. In another aspect, the present disclosure relates to a method of screening a subject for inclusion an NSAID or a PPAR-7 agonist clinical trial. In another aspect, the present disclosure relates to a method of determining a surrogate outcome of an NSAID or a PPAR-7 agonist clinical trial. In yet another aspect, the present disclosure relates to a method of treating an Alzheimer's disease patient having both a proinflammatory endophenotype profile and a metabolic endophenotype profile with a PPAR-7 agonist to improve cognition or to prevent cognitive decline or dysfunction in the patient.

Abstract: The present invention includes methods for selecting a therapy for improved cognition as well as prevention of cognitive loss/dysfunction using one or more endophenotypes comprising: obtaining a sample from a subject; measuring biomarkers that differentiate between an inflammatory, a metabolic, a neurotrophic, and a depressive endophenotype; and selecting a course of treatment for the subject based on whether the subject is scored as having a high or a low endophenotype for one or more of the inflammatory, a metabolic, a neurotrophic, and a depressive endophenotypes.

Abstract: The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNF? biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.

Abstract: The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNF? biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.

Abstract: The present invention includes a method of treating or preventing memory loss in a subject suffering from a memory loss-related disease or aging, comprising, consisting essentially of, or consisting of, administering an effective amount of a serotonin-norepinephrine reuptake inhibitor (SNRI) to the subject, wherein the serotonin-norepinephrine reuptake inhibitor is duloxetine or active derivative thereof, such as a subject with memory complaints as part of the aging process, mild cognitive impairment, Alzheimer's disease or dementia and an elevated depressive endophenotype genotype (DepE).

Abstract: The present invention includes methods and kits for measuring a level of four or more biomarkers selected from IL1, IL7, TNF?, IL5, IL6, CRP, IL10, TNC, ICAM1, FVII, I309, TNFR1, A2M, TARC, adiponectin, MIP1, eotaxin3, sVCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, ?-synuclein, Ab40, Ab42, tau, alpha-syn, and NfL in a sample separated from a human subject in the primary care setting with neurological disease with a nucleic acid, an immunoassay or an enzymatic activity assay.

Abstract: The present invention includes a method for identifying a patient response to treatment for Alzheimer's Disease with a non-steroidal anti-inflammatory drug (NSAID) or an acetylcholinesterase (AChE) inhibitor drug comprising: obtaining a blood or serum sample from the patient; determining the presence of a proinflammatory endophenotype in the blood or serum sample of the patient; using the proinflammatory endophenotype to detect treatment response (a responder, a stable, a non-responder or an adverse responder); and treating the patient with the NSAID or the AChE inhibitor if the patient is in the responder or the stable treatment response phenotype group; or preventing a treatment with the NSAID or the AChE inhibitor if the patient is a non-responder or an adverse responder.

Abstract: The present invention includes methods for selecting a therapy for improved cognition as well as prevention of cognitive loss/dysfunction using one or more endophenotypes comprising: obtaining a sample from a subject; measuring biomarkers that differentiate between an inflammatory, a metabolic, a neurotrophic, and a depressive endophenotype; and selecting a course of treatment for the subject based on whether the subject is scored as having a high or a low endophenotype for one or more of the inflammatory, a metabolic, a neurotrophic, and a depressive endophenotypes.

Abstract: The present invention includes methods and kits for measuring a level of four or more biomarkers selected measuring a level of four or more biomarkers selected from ILL IL7, TNF?, IL5, IL6, CRP, IL10, TNC, ICAM1, FVII, I309, TNFR1, A2M, TARC, adiponectin, MIP1, eotaxin3, sVCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, and ?-synuclein, A?40, A?42, tau, ?-synuclein, and NfL in a sample separated from a human subject in the primary care setting with neurological disease with a nucleic acid, an immunoassay or an enzymatic activity assay.

Abstract: The present disclosure relates to a method of treating a subject having a proinflammatory endophenotype profile with celecoxib or naproxen to improve cognition or to prevent cognitive decline or dysfunction in the subject. In another aspect, the present disclosure relates to a method of screening a subject for inclusion an NSAID or a PPAR-? agonist clinical trial. In another aspect, the present disclosure relates to a method of determining a surrogate outcome of an NSAID or a PPAR-? agonist clinical trial. In yet another aspect, the present disclosure relates to a method of treating an Alzheimer's disease patient having both a proinflammatory endophenotype profile and a metabolic endophenotype profile with a PPAR-? agonist to improve cognition or to prevent cognitive decline or dysfunction in the patient.

Abstract: The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, ?2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-?), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.

Abstract: The present invention includes methods and kits for measuring a level of four or more biomarkers selected from IL1, IL7, TNF?, IL5, IL6, CRP, IL10, TNC, ICAM1, FVII, I309, TNFR1, A2M, TARC, adiponectin, MIP1, eotaxin3, sVCAM1, TPO, FABP, IL18, B2M, SAA, PPY, DJ1, ?-synuclein, Ab40, Ab42, tau, alpha-syn, and NfL in a sample separated from a human subject in the primary care setting with neurological disease with a nucleic acid, an immunoassay or an enzymatic activity assay.

Abstract: The present invention includes methods for selecting a therapy for improved cognition as well as prevention of cognitive loss/dysfunction using one or more endophenotypes comprising: obtaining a sample from a subject; measuring biomarkers that differentiate between an inflammatory, a metabolic, a neurotrophic, and a depressive endophenotype; and selecting a course of treatment for the subject based on whether the subject is scored as having a high or a low endophenotype for one or more of the inflammatory, a metabolic, a neurotrophic, and a depressive endophenotypes.

Abstract: The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNF biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.